Diamyd Medical - Targeting the Underlying Causes of Diabetes

Årsstämma

Aktieägarna i Diamyd Medical AB (publ) kallas härmed till årsstämma torsdagen den 21 november 2019, kl. 17.00 på Hotell Kung Carl, Birger Jarlsgatan 21 i Stockholm. Sista datum för anmälan är den 15 november.

Till Anmälan

Press Releases

November 11, 2019

Positive safety review of Remygen^® gives clearance to start next part of Phase I/II trial in type 1 diabetes...

Events & Mediawatch

November 8, 2019 Sweden

Bolagspresentation från Stora Aktiedagen 4 november

Calendar

Data pager
Data pager
1 2

November 21, 2019

Annual General Meeting

Annual General Meeting 2018/2019

January 22, 2020

Quarterly Report I

Quarterly Report 1 2019/2020

March 25, 2020

Quarterly Report II

Quarterly Report 2 2019/2020

June 24, 2020

Quarterly Report III

Quarterly Report 3 2019/2020

Financial Reports

October 2, 2019
Year-End Report 18/19

We diligently focus on advancing treatments that are safe, accessible and that intercept the disease early before complications begin to manifest.

Ulf Hannelius
President and CEO, Diamyd Medical AB

Diamyd Medical is a Swedish clinical-stage diabetes company active in the field of pharmaceutical development
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read more

Diabetes

10-20% of the more than 400 million living with diabetes suffer from the autoimmune form of the disease, where the immune system destroys the insulin-producing cells. Preserving the insulin producing ability may decrease the risk of complications among patients with autoimmune diabetes by 60-80 percent.
Read more

Products

The antigen-specific immunotherapy Diamyd^® and the regenerative and immunomodulatory therapy Remygen^® are two novel disease-modifying drugs in clinical development phase, aiming to preserve and regenerate the patients’ own insulin production.
Read more

Clinical Trials

The efficacy of intralymphatic administration of Diamyd^® on preserving the insulin producing ability in type 1 diabetes is being confirmed in the Phase IIb trial DIAGNODE-2. The safety and efficacy of Remygen^® on stimulating growth of insulin producing cells in type 1 diabetes is being evaluated for the first time in the Phase I/II trial ReGenerate-1.